TY - JOUR
T1 - Cognitive impairment in the schizophrenia spectrum
T2 - What is the evidence for similarity to schizophrenia?
AU - McClure, Margaret M.
AU - Zegarelli, Gayle
AU - Bowie, Christopher R.
AU - Mitropoulou, Vivian
AU - Siever, Larry J.
AU - Harvey, Philip D.
PY - 2006/9
Y1 - 2006/9
N2 - Cognitive dysfunction is a core component of schizophrenia and is strongly related to functional outcome. Schizotypal personality disorder (SPD) appears closely linked to schizophrenia in terms of biology, phenomenology, outcome, and treatment response. Individuals with SPD demonstrate a similar pattern of cognitive deficits, albeit with less severity in most areas, to individuals with schizophrenia, with core impairments in working memory, context processing, and processing capacity. The validity of the SPD cognitive profile is thus discussed in terms of these areas of impairment that are as great as those in schizophrenia, which lends support to the relationship between schizophrenia and SPD.
AB - Cognitive dysfunction is a core component of schizophrenia and is strongly related to functional outcome. Schizotypal personality disorder (SPD) appears closely linked to schizophrenia in terms of biology, phenomenology, outcome, and treatment response. Individuals with SPD demonstrate a similar pattern of cognitive deficits, albeit with less severity in most areas, to individuals with schizophrenia, with core impairments in working memory, context processing, and processing capacity. The validity of the SPD cognitive profile is thus discussed in terms of these areas of impairment that are as great as those in schizophrenia, which lends support to the relationship between schizophrenia and SPD.
UR - https://www.scopus.com/pages/publications/33845342561
UR - https://www.scopus.com/pages/publications/33845342561#tab=citedBy
U2 - 10.1007/BF02629335
DO - 10.1007/BF02629335
M3 - Review article
AN - SCOPUS:33845342561
SN - 1545-8083
VL - 4
SP - 128
EP - 133
JO - Current Psychosis and Therapeutics Reports
JF - Current Psychosis and Therapeutics Reports
IS - 3
ER -